Literature DB >> 25917398

Angiotensin II receptor blockers: a new possible treatment for chronic migraine?

Caterina Disco1, Ferdinando Maggioni, Giorgio Zanchin.   

Abstract

The objective is to suggest a possible role of different angiotensin receptor blockers in the treatment of chronic migraine, especially in hypertensive subjects. Chronic migraine is a highly disabling disorder affecting between 1.4 and 2.2 % of the general population. Despite many pharmacological and non-pharmacological treatments proposed, the results are rather discouraging. Therefore, we believe that should be highlighted all the possible therapies that may lead to an improvement of the symptomatology. Particularly, data available on efficacy of ARBs in preventing chronic migraine are poor. Methods include case reports, literature review and discussion. We report three cases recently treated with angiotensin II receptor blockers that showed a significant improvement, never previously presented with more conventional treatments, including beta blockers. In all three cases, we obtained the reversibility from a chronic migraine to an episodic. Taking a cue from this observation, we consider desirable large controlled, randomized trials to assess the effectiveness of ARBs both in CM hypertensive patients and in patients who do not require anti-hypertensive therapy; furthermore are desirable comparative studies between the various ARB inhibitors to assay any intermolecular differences in efficacy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25917398     DOI: 10.1007/s10072-015-2217-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  10 in total

1.  Detection of possible factors favouring the evolution of migraine without aura into chronic migraine.

Authors:  G C Manzoni; L L Lombardi; S Lana; M Maffezzoni; C Camarda; P Torelli
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

2.  The International Classification of Headache Disorders, 3rd edition (beta version).

Authors: 
Journal:  Cephalalgia       Date:  2013-07       Impact factor: 6.292

3.  A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study.

Authors:  Lars J Stovner; Mattias Linde; Gøril B Gravdahl; Erling Tronvik; Anne H Aamodt; Trond Sand; Knut Hagen
Journal:  Cephalalgia       Date:  2013-12-11       Impact factor: 6.292

4.  Angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans): similarities and differences.

Authors:  P A van Zwieten
Journal:  Neth Heart J       Date:  2006-11       Impact factor: 2.380

5.  Prevention of migraine with olmesartan in patients with hypertension/prehypertension.

Authors:  James A Charles; Seymour Jotkowitz; Lawrence H Byrd
Journal:  Headache       Date:  2006-03       Impact factor: 5.887

6.  Blockade of AT1 receptor partially restores vasoreactivity, NOS expression, and superoxide levels in cerebral and carotid arteries of hindlimb unweighting rats.

Authors:  Ran Zhang; Yun-Gang Bai; Le-Jian Lin; Jun-Xiang Bao; Yu-Yang Zhang; Hao Tang; Jiu-Hua Cheng; Guo-Liang Jia; Xin-Ling Ren; Jin Ma
Journal:  J Appl Physiol (1985)       Date:  2008-11-06

Review 7.  The epidemiology of chronic daily headache.

Authors:  Lynn A Midgette; Ann I Scher
Journal:  Curr Pain Headache Rep       Date:  2009-02

8.  Microinjection of angiotensin II in the caudal ventrolateral medulla induces hyperalgesia.

Authors:  J Marques-Lopes; M Pinto; D Pinho; M Morato; D Patinha; A Albino-Teixeira; I Tavares
Journal:  Neuroscience       Date:  2008-12-07       Impact factor: 3.590

9.  Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial.

Authors:  H C Diener; A Gendolla; A Feuersenger; S Evers; A Straube; H Schumacher; G Davidai
Journal:  Cephalalgia       Date:  2009-09       Impact factor: 6.292

10.  Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.

Authors:  Erling Tronvik; Lars J Stovner; Grethe Helde; Trond Sand; Gunnar Bovim
Journal:  JAMA       Date:  2003-01-01       Impact factor: 56.272

  10 in total
  2 in total

Review 1.  Headache and arterial hypertension.

Authors:  Cinzia Finocchi; Davide Sassos
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

2.  Treatment with telmisartan, a long-acting angiotensin II receptor blocker, prevents migraine attacks in Japanese non-responders to lomerizine.

Authors:  Ken Ikeda; Sayori Hanashiro; Yuichi Ishikawa; Masahiro Sawada; Maya Kyuzen; Harumi Morioka; Junya Ebina; Junpei Nagasawa; Masaru Yanagihashi; Ken Miura; Takehisa Hirayama; Takanori Takazawa; Osamu Kano; Kiyokazu Kawabe; Yasuo Iwasaki
Journal:  Neurol Sci       Date:  2017-02-21       Impact factor: 3.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.